Surgery Partners Analyst Price Targets

Wall Street analyst price targets and consensus rating for Surgery Partners (SGRY).

Price Target Range — 11 Quarters

Analyst Consensus — 9 Analysts

8Buy

1Hold

Consensus RatingBuy# Analysts9Avg. Consensus PT$24Upside to Avg. PT+60.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 30, 2026	RBC Capital	Ben Hendrix	Maintained	Outperform	$19
Sep 18, 2026	TD Cowen	Ryan Langston	Maintained	Buy	$19
Sep 14, 2026	JP Morgan	Benjamin Rossi	PT Raise	Neutral	$14→$15
Aug 11, 2026	TD Cowen	Ryan Langston	PT Raise	Buy	$17→$19
Aug 11, 2026	RBC Capital	Ben Hendrix	PT Cut	Outperform	$20→$19
Aug 11, 2026	Cantor Fitzgerald	Sarah James	Maintained	Overweight	$18
Mar 5, 2026	TD Cowen	Ryan Langston	PT Cut	Buy	$28→$20
Mar 5, 2026	UBS	A.J. Rice	PT Cut	Buy	$29→$21
Mar 5, 2026	Mizuho	Ann Hynes	PT Cut	Outperform	$19→$17
Mar 4, 2026	RBC Capital	Ben Hendrix	PT Cut	Outperform	$31→$20
Mar 3, 2026	Barclays	Andrew Mok	PT Cut	Equal-Weight	$18→$14
Dec 18, 2025	Mizuho	Ann Hynes	PT Cut	Outperform	$22→$19
Nov 24, 2025	JP Morgan	Benjamin Rossi	PT Cut	Neutral	$27→$20
Nov 21, 2025	Barclays	Andrew Mok	PT Cut	Equal-Weight	$24→$18
Nov 17, 2025	Mizuho	Ann Hynes	PT Cut	Outperform	$28→$22
Nov 13, 2025	UBS	A.J. Rice	PT Cut	Buy	$34→$29
Nov 11, 2025	RBC Capital	Ben Hendrix	PT Cut	Outperform	$35→$31
Nov 11, 2025	Benchmark	Bill Sutherland	PT Cut	Buy	$35→$30
Oct 7, 2025	Cantor Fitzgerald	Sarah James	Maintained	Overweight	$36
Sep 18, 2025	JP Morgan	Benjamin Rossi	Assumes	Neutral	$27

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
RBC Capital Reiterates Outperform on Surgery Partners, Maintains $19 Price Target

RBC Capital analyst Ben Hendrix reiterates Surgery Partners (NASDAQ:SGRY) with a Outperform and maintains $19 price target.

Benzinga Newsdesk

PRO
TD Cowen Reiterates Buy on Surgery Partners, Maintains $19 Price Target

TD Cowen analyst Ryan Langston reiterates Surgery Partners (NASDAQ:SGRY) with a Buy and maintains $19 price target.

Benzinga Newsdesk

PRO
JP Morgan Maintains Neutral on Surgery Partners, Raises Price Target to $15

JP Morgan analyst Benjamin Rossi maintains Surgery Partners (NASDAQ:SGRY) with a Neutral and raises the price target from $14 to $15.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Surgery Partners, Raises Price Target to $19

TD Cowen analyst Ryan Langston maintains Surgery Partners (NASDAQ:SGRY) with a Buy and raises the price target from $17 to $19.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Surgery Partners, Lowers Price Target to $19

RBC Capital analyst Ben Hendrix maintains Surgery Partners (NASDAQ:SGRY) with a Outperform and lowers the price target from $20 to $19.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on Surgery Partners, Maintains $18 Price Target

Cantor Fitzgerald analyst Sarah James reiterates Surgery Partners (NASDAQ:SGRY) with a Overweight and maintains $18 price target.

Benzinga Newsdesk

Surgery Partners Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Surgery Partners Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
RBC Capital Reiterates Outperform on Surgery Partners, Maintains $19 Price Target

PRO
TD Cowen Reiterates Buy on Surgery Partners, Maintains $19 Price Target

PRO
JP Morgan Maintains Neutral on Surgery Partners, Raises Price Target to $15

PRO
TD Cowen Maintains Buy on Surgery Partners, Raises Price Target to $19

PRO
RBC Capital Maintains Outperform on Surgery Partners, Lowers Price Target to $19

PRO
Cantor Fitzgerald Reiterates Overweight on Surgery Partners, Maintains $18 Price Target

People Also Watch

People Also Watch

Surgery Partners Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Surgery Partners Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORBC Capital Reiterates Outperform on Surgery Partners, Maintains $19 Price Target

PROTD Cowen Reiterates Buy on Surgery Partners, Maintains $19 Price Target

PROJP Morgan Maintains Neutral on Surgery Partners, Raises Price Target to $15

PROTD Cowen Maintains Buy on Surgery Partners, Raises Price Target to $19

PRORBC Capital Maintains Outperform on Surgery Partners, Lowers Price Target to $19

PROCantor Fitzgerald Reiterates Overweight on Surgery Partners, Maintains $18 Price Target

People Also Watch

People Also Watch

PRO
RBC Capital Reiterates Outperform on Surgery Partners, Maintains $19 Price Target

PRO
TD Cowen Reiterates Buy on Surgery Partners, Maintains $19 Price Target

PRO
JP Morgan Maintains Neutral on Surgery Partners, Raises Price Target to $15

PRO
TD Cowen Maintains Buy on Surgery Partners, Raises Price Target to $19

PRO
RBC Capital Maintains Outperform on Surgery Partners, Lowers Price Target to $19

PRO
Cantor Fitzgerald Reiterates Overweight on Surgery Partners, Maintains $18 Price Target